We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF
IHE

95 hedge funds and large institutions have $348M invested in iShares US Pharmaceuticals ETF in 2017 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 24 increasing their positions, 37 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.74% more ownership

Funds ownership: 145.48% → 148.22% (+2.7%)

0% more capital invested

Capital invested by funds: $348M → $348M (+$439K)

2% less funds holding

Funds holding: 97 → 95 (-2)

22% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 9

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

35% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 37

Holders
95
Holders Change
-2
Holders Change %
-2.06%
% of All Funds
2.37%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
7
Increased
24
Reduced
37
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$13.4M
2
MML Investors Services
MML Investors Services
Massachusetts
+$5.29M
3
CS
Credit Suisse
Switzerland
+$1.48M
4
Bank of America
Bank of America
North Carolina
+$851K
5
IWM
IHT Wealth Management
Illinois
+$613K

Top Sellers

1
MTWSIF
Mivtachim The Workers Social Insurance Fund
Israel
-$5.78M
2
Citadel Advisors
Citadel Advisors
Florida
-$5.7M
3
MIAN
Mariner Independent Advisor Network
Kansas
-$5.5M
4
TSS
Two Sigma Securities
New York
-$4.95M
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$2.32M
Name Holding Trade Value Shares
Change 		Change in
Stake
WAM
76
Wealthspire Advisors (Maryland)
Maryland
$78K +$75.8K +1,500 New
MWM
77
MinichMacGregor Wealth Management
New York
$61K -$33.4K -660 -36%
FANJ
78
Financial Architects (New Jersey)
New Jersey
$58K – – –
FCMT
79
Founders Capital Management (Texas)
Texas
$44K – – –
WTC
80
WhitTier Trust Company
Nevada
$39K – – –
FFW
81
Fusion Family Wealth
New York
$26K – – –
Northwestern Mutual Wealth Management
82
Northwestern Mutual Wealth Management
Wisconsin
$24K – – –
BWA
83
BDO Wealth Advisors
Florida
$21K +$20.9K +414 New
AA
84
AlphaMark Advisors
Kentucky
$18K – – –
JCM
85
Jacobi Capital Management
Pennsylvania
$17K +$16.7K +330 New
CDIA
86
Capital Directions Investment Advisors
Georgia
$16K – – –
DSC
87
Duncker Streett & Co
Missouri
$16K – – –
Fifth Third Bancorp
88
Fifth Third Bancorp
Ohio
$14K – – –
WIM
89
Westside Investment Management
California
$8.48K – – –
CFD
90
Creative Financial Designs
Indiana
$6K -$20.5K -405 -77%
BC
91
Bartlett & Co
Ohio
$5K – – –
DADC
92
D.A. Davidson & Co
Montana
$5K – – –
MA
93
MCF Advisors
Kentucky
$2K +$2.12K +42 New
IWM
94
IHT Wealth Management
Illinois
$31 +$613K +12,129 +851%
MTWSIF
95
Mivtachim The Workers Social Insurance Fund
Israel
– -$5.78M -114,900 Closed
MIAN
96
Mariner Independent Advisor Network
Kansas
– -$5.5M -109,218 Closed
Bank of New York Mellon
97
Bank of New York Mellon
New York
– -$215K -4,278 Closed
GWS
98
Glassman Wealth Services
Virginia
– -$70K -1,401 Closed
VWM
99
Valley Wealth Managers
New Jersey
– -$45K -900 Closed
AP
100
Advisors Preferred
Maryland
– -$20 -393 Closed
1 2 3
4
5

IHE Hedge Fund Activity: Q2 2017 in Review

95 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q2 2017, worth a combined $348M — up 0.13% from $348M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of IHE and 7 opened new positions — a net loss of 2 holders — while 37 trimmed existing stakes and 24 added.

The largest buyer was Morgan Stanley, adding an estimated $13.4M. The largest seller was Mivtachim The Workers Social Insurance Fund, exiting entirely with an estimated $5.78M sold.

  • 95 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q2 2017, down from 97 in Q1 2017.
  • Funds reported $348M of iShares US Pharmaceuticals ETF stock for Q2 2017, up 0.13% quarter-over-quarter.
  • 7 funds opened new iShares US Pharmaceuticals ETF positions in Q2 2017 and 9 closed out, a net change of -2 holders.
  • The largest iShares US Pharmaceuticals ETF buyer in Q2 2017 was Morgan Stanley, an estimated $13.4M added.
  • The largest iShares US Pharmaceuticals ETF seller in Q2 2017 was Mivtachim The Workers Social Insurance Fund, an estimated $5.78M sold.

Based on aggregated 13F filings for Q2 2017.